Citigroup Inc 4 D Molecular Therapeutics, Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 82,810 shares of FDMT stock, worth $862,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,810

Previous 153,284 45.98%

Holding current value

$862,052

Previous $4.88 Million 64.41%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$20.93 - $30.01 $1.48 Million - $2.11 Million	-70,474 Reduced 45.98%	82,810 $1.74 Million
Q1 2024 May 10, 2024	BUY	$17.03 - $35.87 $1.91 Million - $4.02 Million	111,976 Added 271.08%	153,284 $4.88 Million
Q4 2023 Feb 09, 2024	SELL	$9.76 - $21.25 $130,696 - $284,558	-13,391 Reduced 24.48%	41,308 $836,000
Q3 2023 Nov 09, 2023	SELL	$12.64 - $19.76 $43,709 - $68,330	-3,458 Reduced 5.95%	54,699 $696,000
Q2 2023 Aug 10, 2023	SELL	$15.16 - $23.26 $811,378 - $1.24 Million	-53,521 Reduced 47.92%	58,157 $1.05 Million
Q1 2023 May 11, 2023	BUY	$15.45 - $23.19 $1.33 Million - $1.99 Million	85,862 Added 332.59%	111,678 $1.92 Million
Q4 2022 Feb 09, 2023	BUY	$6.85 - $25.46 $109,065 - $405,374	15,922 Added 160.93%	25,816 $573,000
Q3 2022 Nov 10, 2022	SELL	$6.96 - $11.48 $16,307 - $26,897	-2,343 Reduced 19.15%	9,894 $80,000
Q2 2022 Aug 10, 2022	SELL	$5.68 - $15.99 $92,913 - $261,564	-16,358 Reduced 57.21%	12,237 $85,000
Q1 2022 May 12, 2022	SELL	$13.16 - $22.64 $718,233 - $1.24 Million	-54,577 Reduced 65.62%	28,595 $432,000
Q4 2021 Feb 10, 2022	BUY	$19.56 - $32.94 $1.57 Million - $2.65 Million	80,369 Added 2867.25%	83,172 $1.83 Million
Q3 2021 Nov 10, 2021	BUY	$22.73 - $36.04 $63,712 - $101,020	2,803 New	2,803 $76,000

Others Institutions Holding FDMT

# of Institutions

150

Shares Held

56.3M

Call Options Held

55.6K

Put Options Held

167K

View Full List

About 4D Molecular Therapeutics, Inc.

Ticker FDMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,382,400
Market Cap $337M
Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...

More about FDMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account